CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease

Abstract Diagnosis of dementia with Lewy bodies (DLB) is challenging and specific biofluid biomarkers are highly needed. We employed proximity extension-based assays to measure 665 proteins in the cerebrospinal fluid (CSF) from patients with DLB (n = 109), Alzheimer´s disease (AD, n = 235) and cogni...

Full description

Bibliographic Details
Main Authors:	Marta del Campo, Lisa Vermunt, Carel F. W. Peeters, Anne Sieben, Yanaika S. Hok-A-Hin, Alberto Lleó, Daniel Alcolea, Mirrelijn van Nee, Sebastiaan Engelborghs, Juliette L. van Alphen, Sanaz Arezoumandan, Alice Chen-Plotkin, David J. Irwin, Wiesje M. van der Flier, Afina W. Lemstra, Charlotte E. Teunissen
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-09-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-023-41122-y

Similar Items

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
by: Inger van Steenoven, et al.
Published: (2019-10-01)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
by: Yanaika S. Hok‐A‐Hin, et al.
Published: (2023-07-01)

Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
by: Yanaika S. Hok-A-Hin, et al.
Published: (2023-05-01)

Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies
by: Madhurima Chatterjee, et al.
Published: (2020-08-01)

Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies
by: M. van de Beek, et al.
Published: (2020-04-01)

CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals
by: Marta del Campo, et al.
Published: (2024-11-01)

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
by: Katharina Bolsewig, et al.
Published: (2025-01-01)

Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease
by: Meenakshi Dauwan, et al.
Published: (2016-01-01)

EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology
by: Jessica J. van der Zande, et al.
Published: (2018-07-01)

Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results
by: M. van de Beek, et al.
Published: (2021-02-01)

Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach
by: Inger van Steenoven, et al.
Published: (2020-06-01)

Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies
by: Merijn Joling, et al.
Published: (2018-01-01)

Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting
by: Rebecca Z. Rousset, et al.
Published: (2024-10-01)

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease
by: Katheryn A. Q. Cousins, et al.
Published: (2023-05-01)

MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies
by: Anna Inguanzo, et al.
Published: (2023-01-01)

Neuroinflammation is associated with Alzheimer’s disease co-pathology in dementia with Lewy bodies
by: Janna van Wetering, et al.
Published: (2024-05-01)

Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study
by: Merijn Joling, et al.
Published: (2019-01-01)

YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer’s disease and frontotemporal lobar degeneration
by: Yanaika S. Hok-A-Hin, et al.
Published: (2022-07-01)

Effect of long‐term storage in biobanks on cerebrospinal fluid biomarker Aβ1‐42, T‐tau, and P‐tau values
by: Eline A.J. Willemse, et al.
Published: (2017-01-01)

Cognitive Writing Process Characteristics in Alzheimer’s Disease
by: Catherine Meulemans, et al.
Published: (2022-07-01)

Determinants of informal care time, distress, depression, and quality of life in care partners along the trajectory of Alzheimer's disease
by: Arenda Mank, et al.
Published: (2023-04-01)

Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface
by: Lisa Vermunt, et al.
Published: (2022-11-01)

ecpc: an R-package for generic co-data models for high-dimensional prediction
by: Mirrelijn M. van Nee, et al.
Published: (2023-04-01)

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
by: E.E. Wolters, et al.
Published: (2020-01-01)

Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson’s disease
by: Stefanie Smolders, et al.
Published: (2021-02-01)

Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer's disease
by: Sanaz Arezoumandan, et al.
Published: (2024-03-01)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
by: Betty M. Tijms, et al.
Published: (2018-09-01)

Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data
by: Carla Abdelnour, et al.
Published: (2022-01-01)

Grey matter networks in women and men with dementia with Lewy bodies
by: Annegret Habich, et al.
Published: (2024-04-01)

Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An 123I-FP-CIT SPECT study
by: J.J. van der Zande, et al.
Published: (2020-01-01)

Experiences with and perspectives on advance care planning in young- and late- onset dementia: A focus group study with physicians from various disciplines
by: Romy Van Rickstal, et al.
Published: (2023-03-01)

Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease and Vascular Dementia
by: Arianna Romani, et al.
Published: (2020-05-01)

Blood‐based metabolic signatures in Alzheimer's disease
by: Francisca A. deLeeuw, et al.
Published: (2017-01-01)

Adaptive immune changes associate with clinical progression of Alzheimer’s disease
by: Lynn van Olst, et al.
Published: (2024-04-01)

Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline
by: Ingrid S. van Maurik, et al.
Published: (2020-10-01)

123I-MIBG Myocardial Scintigraphy in the Diagnosis of Lewy Body Dementia
by: M. Marquié Sayagués, et al.
Published: (2010-01-01)

Callosal circularity as an early marker for Alzheimer's disease
by: Jeroen Van Schependom, et al.
Published: (2018-01-01)

Plasma Alzheimer's disease markers and MRI load of vascular pathology and neurodegeneration: the SMART-MR Study
by: Emma Twait, et al.
Published: (2024-01-01)

Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier
by: Antti Tolonen, et al.
Published: (2018-04-01)

Depressive Symptoms in the Elderly—An Early Symptom of Dementia? A Systematic Review
by: Wietse Wiels, et al.
Published: (2020-02-01)